Hairmaxxing: what the minoxidil and finasteride trend gets right and wrong

Hairmaxxing is the online project of defending a hairline as aggressively and as early as possible — typically by stacking topical or oral minoxidil, finasteride, a dermaroller and a ketoconazole shampoo into a daily regimen, often begun in the early twenties before much hair has been lost. The trend gets one big thing right: two of these drugs have decades of randomised evidence and do increase hair density. Almost everything layered around that fact — the urgency, the oral-minoxidil hype, the confidence that side effects are a myth — runs ahead of what the evidence supports.

This is standing informational reporting, not medical advice, and these are prescription decisions for a clinician. What follows is what the trials show and where the trend departs from them.

The two drugs that work, and by how much

A Bayesian network meta-analysis of randomised trials in men with androgenetic alopecia put the best-performing treatments at somewhere between 12 and 20 additional hairs per square centimetre over 24 weeks against control [s1]. The node-splitting estimates were 20.0 hairs/cm² for topical minoxidil 5% (95% credible interval 3.7 to 41.0), 19.0 for oral dutasteride 0.5 mg (9.5 to 28.0), 15.0 for topical finasteride 0.25% (0.85 to 30.0) and 12.0 for oral finasteride 1 mg (4.20 to 19.0) [s1]. Those are real effects on a progressive condition. They are not the restoration the category advertises, and the credible intervals overlap almost completely — meaning the data cannot actually rank the drugs against one another, only separate them from doing nothing [s1]. Our male-pattern hair-loss drug evidence review works through that analysis in detail.

The number worth sitting with is the unit: hairs per square centimetre, not a reversed hairline. The drugs slow and partially offset loss; they do not turn back the clock, which is the gap between the evidence and the before-and-after photographs the trend runs on.

The oral-minoxidil hype

The trend's newest enthusiasm is low-dose oral minoxidil, promoted as a stronger, more convenient alternative to the topical solution. The proposal has genuine clinical roots — a review identified 17 studies with 634 patients using oral minoxidil as the primary treatment for hair loss, and found it a reasonable option for people who cannot tolerate the topical form's twice-daily application, texture or scalp irritation [s2]. But the same review frames it as an alternative under medical supervision, not a self-directed upgrade: minoxidil is a blood-pressure drug, and its systemic use carries cardiovascular and fluid-retention considerations plus unwanted body-hair growth that the topical version largely avoids [s2]. "Stronger" is doing a lot of unspoken work in the forum version.

The finasteride side-effect debate, reported carefully

Finasteride's safety is the most contested question in this field, and the trend tends to resolve it in one of two unearned directions — either that side effects are invented, or that "post- finasteride syndrome" is a certainty. The evidence sits between. A meta-analysis of double-blind, placebo-controlled trials found 5-alpha reductase inhibitors carried a 1.57-fold risk of sexual dysfunction (95% confidence interval 1.19 to 2.08), with finasteride specifically at a relative risk of 1.66 (1.20 to 2.30) [s3]. So a real, elevated risk of sexual side effects during treatment is established.

What is far weaker is the data on persistence and severity, because the trials measured it badly. An analysis of 34 finasteride trials found the safety reporting so poor — short, vague, and in some trials reporting no adverse events at all — that the true rate cannot be pinned down, with funnel plots skewed toward underreporting [s4]. The honest position is that finasteride raises sexual side-effect risk while treatment continues, that whether a persistent syndrome exists after stopping is unresolved because the trials were not built to answer it, and that neither of the confident forum verdicts is supported.

What the trend leaves out

Hairmaxxing is overwhelmingly a young-male preoccupation, but the same drug logic and its limits apply more broadly, which our female-pattern hair-loss evidence review covers. And it routinely conflates ordinary pattern balding with unrelated conditions: patchy autoimmune hair loss is a different disease with different, genuinely transformative drugs, as our alopecia areata JAK-inhibitor trials piece explains, and shedding after rapid weight loss on GLP-1 drugs has its own emerging evidence, set out in our GLP-1 and hair-loss systematic review. Matching the treatment to the actual diagnosis is the step the stacking mindset skips.

What to watch

The reasonable core of hairmaxxing is that the two evidence-backed drugs exist and work modestly. The unreasonable parts are the ones the trend adds: the certainty, the self-escalation to oral dosing, and the treatment of a prescription drug's side-effect profile as a settled talking point in either direction. These are decisions for a clinician who can weigh them against an individual's risks — not for a regimen copied from a video.

Sources

• [s1] Relative Efficacy of Conventional Monotherapies and Select Nonconventional, Over-the-Counter Products for Male Androgenetic Alopecia: A Network Meta-Analysis Study — Journal of Cosmetic Dermatology, October 2025. https://doi.org/10.1111/jocd.70483
• [s2] Oral minoxidil treatment for hair loss: A review of efficacy and safety — Journal of the American Academy of Dermatology, July 2020. https://doi.org/10.1016/j.jaad.2020.06.1009
• [s3] Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis — Acta Dermato-Venereologica, 12 September 2018. https://doi.org/10.2340/00015555-3035
• [s4] Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis — JAMA Dermatology, 1 April 2015. https://doi.org/10.1001/jamadermatol.2015.36